ArticleOpen forum infectious diseases2016
End-Stage Liver Disease Is a Strong Predictor of Early Mortality in Cryptococcosis.
Article in Open forum infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 62 citations in OpenAlex.
- Cryptococcal Meningitis: Comparison of Short- (≤ 1 Week) Versus Longer-duration (> 1 Week) Liposomal Amphotericin B Induction Therapy and Factors Associated With Clinical Outcomes in HIV and Non-HIV Patients.Open forum infectious diseases · 2026Trial
- Hypoxemic Respiratory Failure and Coccidioidomycosis-Associated Acute Respiratory Distress Syndrome.Open forum infectious diseases · 2024Trial
- Kupffer cells in liver homeostasis and disease: from immune sentinels to metabolic gatekeepers.Nature reviews. Immunology · 2026Review
- Invasive fungal disease in patients with end-stage liver disease.Infectious diseases & immunity · 2026Review
- Epidemiology and Clinical Features of Cryptococcosis Among Individuals Without HIV Infection: An Observational International Multicenter Study (MSG-11).Open forum infectious diseases · 2026Article
- Article
- High Mortality and Associated Risk Factors in Kidney Transplant Recipients With Cryptococcosis-A Nationwide Cohort Study Over a Decade Using USRDS Data.Open forum infectious diseases · 2025Article
- Invasive fungal infections in patients with liver disease: immunological and clinical considerations for the intensive care unit.Intensive care medicine · 2025Review
- Disseminated cryptococcosis in an HIV patient with hepatitis C as the associated risk factor.Current medical mycology · 2025Article
- Elements of dissemination in cryptococcosis.mBio · 2024Review
- Unmasking the Unusual: Cryptococcal Pericarditis in a Patient with Liver Failure - a Rare Occurrence.The American journal of case reports · 2024Article
- The incidences and clinical outcomes of cryptococcosis in Taiwan: A nationwide, population-based study, 2002-2015.Medical mycology · 2024Article
- Fungal infections in liver cirrhosis.Translational gastroenterology and hepatology · 2024Review
- Dose Optimization of Fluconazole After Initial Treatment Failure in Pulmonary Cryptococcosis in an Obese Patient with Type 2 Diabetes and Cirrhosis: A Case Report.Infection and drug resistance · 2024Article
- Cryptococcal Meningitis Presenting as Chronic Headache in an Apparently Immunocompetent Patient.Cureus · 2023Article
- Case Series of End-Stage Liver Disease Patients with Severe Coccidioidomycosis.Journal of fungi (Basel, Switzerland) · 2023Article
- Article
- Transudative pleural effusion as an initial presentation of a disseminated cryptococcosis infection in a HIV-negative patient with cirrhosis.Medical mycology case reports · 2021Article
- Clinical Predictors Impacting Cryptococcal Dissemination and Poor Outcome in Patients With Cirrhosis.Open forum infectious diseases · 2021Article
- Mechanisms of fungal dissemination.Cellular and molecular life sciences : CMLS · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background. Cryptococcosis in the setting of end-stage liver disease (ESLD) has been associated with high mortality. We sought to compare the outcome of cryptococcal disease in patients with ESLD to that of human immunodeficiency virus (HIV)-positive patients and to those patients without HIV or ESLD. Methods. We assembled a retrospective cohort of 232 consecutive cases of cryptococcosis in our institution, from 2002 to 2014, inclusively. We analyzed the cases for comorbidities, type of infection, and survival. Data were analyzed with t tests, Fishers Exact test, and Kaplan-Meyer analysis. Results. Twenty-five (10.8%) patients with cryptococcal infection had concomitant ESLD; of these, 5 (20%) presented with peritonitis. Most (17 of 25, 68%) did not have any other cause of immunocompromise that has been more classically associated with cryptococcosis. Patients with ESLD had a significantly higher mortality than HIV-positive patients and HIV-negative patients without ESLD (HIVNE) (80% vs 13.6% and 22.7%, respectively; P < .001). In addition, fatal outcome in ESLD patients occurred more rapidly than in HIVNE patients, with a median survival of 6 days (vs 17), despite a comparable time to diagnosis (6.2 vs 6.6 days). Conclusions. Cryptococcosis is an important morbidity in patients with ESLD. Patients with ESLD who are infected with Cryptococcus have a high and rapid mortality. This suggests that a high level of vigilance for cryptococcal infection should be kept in patients with ESLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.